Introduction
Many patients with established coronary heart disease who enter coronary care units with a prolonged attack of ischaemic myocardial pain are on beta-blockers. From a theoretical standpoint it might be expected that this group of patients would be more prone to cardiac failure, syncope, hypotension, and bradycardia at a time when their coronary blood flow was compromised.
A retrospective analysis of 452 patients admitted to the coronary care -unit, Kingston General Hospital, Hull, with ischaemic ,myocardial pain from 1 July 1971 to 30 June 1972 showed that 52 patients were being treated with beta-blockers before admission. A diagnosis of acute myocardial infarction was made in only 22 (42%) of these patients whereas this diagnosis was established in 275 (69%) of the remaining 400 patients who were not on beta-blockers. The incidence of radiological pulmonary oedema, sinus bradycardia, and syncope was similar in both groups. These observations suggested that beta-blockade in coronary artery disease with stable angina might protect against acute myocardial infarction. A prospective study was therefore designed to see whether these initial uncontrolled observations could be substantiated. (Marrott et al., 1973) .
Patients and Methods
Myocardial necrosis without localized infarction was diagnosed in those patients with raised serum enzymes who also developed persistent S-T segment and T-wave changes, other causes of raised serum enzymes having been excluded.
The diagnosis of coronary insufficiency was made in the presence of typical ischaemic cardiac pain without E.C.G. or enzyme evidence of recent infarction or necrosis.
E.C.G.s were recorded on each of the first three days of the patients' stay in the coronary care unit and weekly thereafter unless there was an indication for obtaining further records.
The SGOT was estimated daily for at least the first three days then weekly. The first sample was drawn on the day of admission. SGOT was measured by a modified spectrophotometric method using a reaction rate analyser. The upper limit of normal for our laboratory was 22 IU and the SGOT was considered abnormal if 10% above this limit.
Left heart failure was defined as radiological pulmonary oedema. Lesser degrees of pulmonary congestion were excluded as the amount of observer error (clinical and radiological) in this condition is great.
Statistical analysis of the data was made using the x2 test for two independent samples and the Fisher test of exact probabilities.
Results
The incidence of myocardial infarction, myocardial necrosis without infarction, and coronary insufficiency is shown in table I. Myocardial infarction occurred more often in the control group than in the beta-blocker group (P <0{001). Conversely, the incidence of coronary insufficiency in the beta-blocker group was significantlygreaterthanin the control group (P <0 001). The occurrence of myocardial necrosis without infarction was the same in the two groups. In each group the proportion of patients with myocardial infarction, myocardial necrosis without infarction, and coronary insufficiency who were receiving either propranolol or practolol was similar. The number of patients on oxprenolol was too small for adequate comparison. The incidence of cardiac failure and arrhythmias are shown in tables II and III. While these complications occurred with equal frequency in patients in both groups who had suffered recent myocardial infarction the total number of cases of late cardiac failure and major arrhythmias (ventricular tachycardia, ventricular fibrillation, asystole, and complete heart block) was greater in the control group (P = 0 03, P <0 05 respectively).
Death occurred in nine patients in the beta-blocker group and in 10 controls. Within the beta-blocker group the mortality did not seem to be related to drug dosage, recognizing that the number of patients receiving each drug was small.
Six patients on beta-blockers and four controls had had syncopal episodes before admission, but this was not statistically significant. Fifteen patients on beta-blockers and 12 in the control group had sinus bradycardia (pulse rate less than 50/min). (100) 14 (100) 14 (100) The peak SGOT levels of the two groups are shown in table IV. They were higher in the control group.
There was no significant difference in the time of onset of pain to admission to the coronary care unit (table V), the systolic blood pressure, or pulse rate on admission between the two groups (P >0 05).
In both groups the incidence of myocardial necrosis (with or without infarction) in patients with a previous history of infarction was not significantly different from those without prior infarction. Discussion Beta-receptor antagonists are widely used and of proven benefit in the therapy of angina pectoris (Gillam and Prichard, 1966; Elliott and Stone, 1969; George et al., 1970) . Though the mode of action of these drugs has not been completely elucidated it seems likely that some of their therapeutic effect is due to reduction in myocardial oxygen consumption as a consequence of a decrease in heart rate and mean systolic blood pressure (Taylor, 1973) . They may also be expected to slow the velocity of myocardial contraction as a sequel to blocking the inotropic receptors in the myocardium (Sonnenblick et al., 1965 ). In clinical practice the level of sympathetic overdrive in a patient with prolonged ischaemic myocardial pain is difficult to assess. Nonetheless, it seems probable that establishing beta-blockade in such patients could be of benefit and recently the Boston Group have shown that propranolol was usually rapidly effective in relieving the features of acute myocardial ischaemia in the intermediate coronary syndrome (Fischl et al., 1973) . It is therefore improbable that beta-blockers could prolong ischaemic pain by causing coronary spasm (Carleton and Johnson, 1974) .
In patients with stable angina it has not yet been shown that beta-blockers protect against myocardial infarction, but this may be the explanation of our results provided that the control group of patients is acceptable.
In spite of the prediction that in patients on beta-blockers there would be an increased incidence of cardiac failure, syncope, hypotension, and bradycardia after prolonged ischaemic myocardial pain this was not shown. The greater frequency of late cardiac failure and major arrhythmias in the control group is in accordance with the higher incidence of myocardial infarction in this group.
The similar mortality rate in the two groups suggests that a myocardial infarction sufficiently extensive to be fatal was not prevented by beta-blockade.
In view of the relatively short half life of the beta-blockers (Carruthers et al., 1973 ) their immediate withdrawal after the patients' entry to hospital may explain why there was no observed reduction in the incidence of arrhythmias in patients who had suffered either myocardial necrosis (with or without infarction) or coronary insufficiency.
Established beta-blockade, therefore, in no way prejudices the outcome of patients admitted to hospital with prolonged ischaemic pain. On the contrary, it may protect some patients from the development of myocardial infarction and so enhance their long-term prognosis.
